Emergent Biosolutions, Inc. (NYSE:EBS) will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 5:00 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.emergentbiosolutions.com
Earnings Expectation
Emergent Biosolutions, Inc. is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020. Analysts polled by Thomson Reuters anticipate third quarter income of $ 2.12 per share from revenue of $ 437.93 million. Looking ahead, the full year income are expected at $ 6.73 per share on the revenues of $ 1530.51 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 420.00 million ~ $ 450.00 million
Full Year 2020 topline are forecasted in a range of$ 1,500.00 million ~ $ 1,600.00 million
Click Here For More Historical Outlooks Of Emergent Biosolutions, Inc.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers diseases; and opioids. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine.
